Le Lézard
Classified in: Covid-19 virus
Subject: ATY

ALERT: Investors in NRx Pharmaceuticals, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPW


SAN DIEGO, Jan. 23, 2022 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP; NRXPW) securities between June 1, 2021 and November 4, 2021, both dates inclusive (the "Class Period") have until March 21, 2022 to seek appointment as lead plaintiff in Dal Bosco v. NRx Pharmaceuticals, Inc., No. 22-cv-00066 (D. Del.).  Commenced on January 18, 2022, the NRx Pharma class action lawsuit charges NRx as well as certain of its top executives with violations of the Securities Exchange Act of 1934. 

If you suffered significant losses and wish to serve as lead plaintiff of the NRx Pharma class action lawsuit, please provide your information by clicking here.  You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].  Lead plaintiff motions for the NRx Pharma class action lawsuit must be filed with the court no later than March 21, 2022.

CASE ALLEGATIONS: NRx is a clinical-stage small molecule pharmaceutical company that develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.  NRx's products include, among others, ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure.  In June 2021, NRx announced that it filed an application with the U.S. Food and Drug Administration ("FDA") requesting Emergency Use Authorization ("EUA") for ZYESAMI (Aviptadil-acetate) to treat critically ill COVID-19 patients suffering with respiratory failure.

The NRx Pharma class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the ZYESAMI EUA application contained insufficient data regarding the potential benefits and risks of ZYESAMI; (ii) accordingly, the FDA was unlikely to approve the ZYESAMI EUA application in its present form; and (iii) as a result, NRx's public statements were materially false and misleading at all relevant times.

On November 4, 2021, NRx issued a press release "announc[ing] that the [FDA] has declined to issue an [EUA] for ZYESAMI® (aviptadil).  The FDA stated that it was unable to issue the EUA at this time due to insufficient data regarding the known and potential benefits of the medicine and the known and potential risks of ZYESAMI in patients suffering from Critical COVID-19 with respiratory failure."  On this news, NRx's stock price declined by more than 25%, damaging investors.

Robbins Geller Rudman & Dowd LLP has launched a dedicated SPAC Task Force to protect investors in blank check companies and seek redress for corporate malfeasance.  Comprised of experienced litigators, investigators, and forensic accountants, the SPAC Task Force is dedicated to rooting out and prosecuting fraud on behalf of injured SPAC investors.  The rise in blank check financing poses unique risks to investors.  Robbins Geller's SPAC Task Force represents the vanguard of ensuring integrity, honesty, and justice in this rapidly developing investment arena.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased NRx securities during the Class Period to seek appointment as lead plaintiff in the NRx Pharma class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the NRx Pharma class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the NRx Pharma class action lawsuit.  An investor's ability to share in any potential future recovery of the NRx Pharma class action lawsuit is not dependent upon serving as lead plaintiff. 

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. law firm representing investors in securities class actions.  Robbins Geller attorneys have obtained many of the largest shareholder recoveries in history, including the largest securities class action recovery ever ? $7.2 billion ? in In re Enron Corp. Sec. Litig.  The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for recovering $1.6 billion for investors that year, more than double the amount recovered by any other securities plaintiffs' firm.  Please visit http://www.rgrdlaw.com for more information. 

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Contact:
            Robbins Geller Rudman & Dowd LLP
            655 W. Broadway, San Diego, CA  92101 
            J.C. Sanchez, 800-449-4900
            [email protected]

https://www.linkedin.com/company/rgrdlaw
https://twitter.com/rgrdlaw
https://www.facebook.com/rgrdlaw

SOURCE Robbins Geller Rudman & Dowd LLP


These press releases may also interest you

at 06:05
Pregistry, a leader in the development and conduct of observational studies during pregnancy, announced today the appointment of Dr. Cheryl Renz as the company's Chief Medical Officer (CMO). In this role, Dr. Renz will oversee medical and...

at 06:05
The "Per Diem Nurse Staffing Market Research Report by Service (Emergency Department and Home Care Services), End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19"...

at 06:00
The "Home Entertainment Devices Market by Type, Mode of Connectivity Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2022-2031" report has been added to ResearchAndMarkets.com's offering. The global home...

at 06:00
The "Channel Marketing Software Market Research Report by Type (B2B and B2C), Industry, Deployment, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to...

at 06:00
The "Mobile & Wireless Backhaul Market Research Report by Component (Equipment and Services), Network Technology, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has...

at 06:00
Kiwetinohk Energy Corp. today announced an acceleration and expansion of its 2022 upstream operational program, resulting in increased 2022 guidance.  The momentum of the upstream program, as announced in conjunction with the Company's first quarter...



News published on 23 january 2022 at 00:03 and distributed by: